Beyond CAR-T: How Dendritic-Cell Therapy Drives Remissions in Melanoma and Pancreatic Cancer

When patients hear about cellular immunotherapy, the name that comes to mind is almost always CAR-T. Yet CAR-T is only one actor in a larger story. The immune response it aims to unleash is initiated by a different cell entirely: the dendritic cell. Understanding dendritic cells matters because they are the immune system's most powerful antigen-presenting cell, the hinge between innate and adaptive immunity, and the basis of a class of treatments known as DC vaccines.

What dendritic cells do

Dendritic cells take up, process and present antigen, then deliver that information together with co-stimulatory signals and cytokines to T cells. They are the reason a naive T cell becomes an effector cell capable of killing tumours, and why some of those effectors become long-lived memory cells that respond fast on re-exposure. By function, the family splits into classical dendritic cells, plasmacytoid dendritic cells and monocyte-derived inflammatory dendritic cells. Classical type 1 dendritic cells are the most important for launching CD8-positive T-cell responses against tumours; type 2 mainly activate CD4-positive T cells; plasmacytoid cells are weaker at activating T cells but strong at producing type 1 interferon; and monocyte-derived cells, made in the lab from monocytes under GM-CSF and IL-4, drive inflammation and can also promote T-cell reactions.

Because their job is to start and shape immune responses, dendritic cells were an obvious therapeutic target. The approach is to take precursor cells, mature them into dendritic cells outside the body, load them with tumour antigen, and return them so they activate resting T cells. Because the mechanism mirrors a vaccine, the therapy is usually called a DC vaccine.

A phase 3 trial in melanoma

The strongest evidence comes from MIND-DC, a randomised phase 3 trial of autologous dendritic-cell therapy in stage IIIB or IIIC melanoma, reported in Nature Communications. The trial enrolled 148 patients, randomised to the dendritic-cell group of ninety-nine or a control group of forty-nine. At data cutoff the median follow-up was 56.3 months.

The dendritic-cell group had a median relapse-free survival of 12.7 months and a two-year relapse-free survival of 36.8 per cent. The two-year overall survival was 84.7 per cent. Beyond the averages, one patient's imaging told the story most clearly: a substantial lung metastasis shrank markedly after a single cycle of dendritic-cell therapy. For a locally advanced or metastatic melanoma, that kind of response is the result clinicians hope for and rarely see from a single modality.

A complete response in pancreatic cancer

A 2025 case report from Japan shows the other end of the evidence spectrum: a single, carefully documented patient. A seventy-year-old man had undergone surgery for early pancreatic ductal adenocarcinoma, then two years later was found to have a twenty-eight-millimetre recurrence at the pancreatic resection margin, with metastases to the mesentery, paratracheal nodes and right liver lobe. He was stage IV and could not tolerate chemotherapy, which had caused chronic fatigue, appetite loss, weight loss and bloating.

He instead received a triple cellular immunotherapy: an alpha-galactosylceramide-pulsed dendritic-cell vaccine to activate NKT-cell innate immunity, a WT-1 dendritic-cell vaccine to present tumour antigen and induce specific cytotoxic T cells, and NK-cell therapy to heighten natural cytotoxicity. Within about three months, tumour markers fell markedly, CA19-9 from 88.3 to 54.4 and DU-PAN-2 from 267 to 76. Liver function and inflammation improved. A PET-CT showed the pancreatic lesion regressed and the mesenteric, paratracheal and liver metastases had disappeared entirely. The overall result was complete response.

How this differs from CAR-T

It is worth being precise about the distinction. CAR-T re-engineers a patient's own T cells into a living drug that hunts a specific target. Dendritic-cell therapy does not re-engineer T cells at all; it educates the patient's existing immune system by presenting tumour antigen through its natural gateway. Both are cellular immunotherapies, and both are advancing in China's clinical ecosystem, but they work through different steps of the same pathway. That is why a patient weighing options should know both exist, and why a centre's real strength is offering the right mechanism for the right tumour rather than a single branded approach.